您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (9): 65-70.doi: 10.6040/j.issn.1671-7554.0.2014.830

• 临床医学 • 上一篇    下一篇

肾单位保留术和肾癌根治术治疗T1b期肾癌的Meta分析

苏静1, 薛娇美1, 孙菲菲1, 郭兆新2, 程翔宇2, 孟力维2, 刘照旭2   

  1. 1. 山东大学护理学院, 山东 济南 250012;
    2. 山东大学齐鲁医院泌尿外科, 山东 济南 250012
  • 收稿日期:2014-11-17 出版日期:2015-09-10 发布日期:2015-09-10
  • 通讯作者: 刘照旭。E-mail:zhaoxvliu@sdu.edu.cn E-mail:zhaoxvliu@sdu.edu.cn

Comparison of nephron-sparing surgery and radical nephrectomy for T1b renal cell carcinoma: a Meta-analysis

SU Jing1, XUE Jiaomei1, SUN Feifei1, GUO Zhaoxin2, CHENG Xiangyu2, MENG Liwei2, LIU Zhaoxu2   

  1. 1. School of Nursing, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2014-11-17 Online:2015-09-10 Published:2015-09-10
  • Contact: 刘照旭。E-mail:zhaoxvliu@sdu.edu.cn E-mail:zhaoxvliu@sdu.edu.cn

PDF (PC)

249

摘要： 目的 比较肾单位保留术(NSS)和肾癌根治术(RN)治疗对侧肾功能正常的T1b期原发性肾癌患者预后结局。方法 计算机检索PubMed、Elsevier ScienceDirect、Web of Science、Co-chrane Library、中国期刊全文数据库(CNKI)、中国生物医学文献数据库、中文科技期刊数据库和万方数据库,查找所有比较NSS和 RN 治疗T1b期肾癌的队列研究,检索时限均为建库至 2014年 9月 30 日。同时手工检索纳入文献的参考文献。按纳入排除标准筛选文献、提取资料和评价质量后,采用Stata12.0软件进行Meta 分析。结果 共纳入11项研究,23939例患者。Meta分析结果显示,NSS和RN治疗T1b期肾癌的5年[RR=1.05, 95%CI(0.98, 1.13)]、7年[RR=1.02, 95%CI(0.94, 1.10)]、10年[RR=1.30, 95%CI(0.96, 1.77)]的生存率差异无统计学意义;NSS的5年肿瘤特异生存率高于RN[RR=1.11, 95%CI(1.06, 1.16)]; NSS的5年肿瘤特异死亡率低于RN[RR=0.70, 95%CI(0.55, 0.90)]; NSS的肿瘤转移率低于RN[RR=0.38, 95%CI(0.22, 0.66)]。结论 对于纳入本研究的患者,NSS和RN比较,患者的5、7、10年生存率相似,但NSS 5年肿瘤特异生存率高,5年肿瘤特异死亡率、转移率低。

关键词: Meta分析, 肾单位保留术, T1b期肾癌, 预后, 肾癌根治术

Abstract: Objective To compare the outcomes of nephron-sparing surgery (NSS) and radical nephrectomy (RN) in treating T1b renal cell carcinoma (RCC). Methods The following databases including Pubmed, Elsevier ScienceDirect, Web of Science, Co-chrane library, CNKI, CBM, VIP and WanFang were searched electronically from the date of their establishment to Sept. 2014 to collect cohort studies on NSS versus RN in the treatment of T1b RCC, and the references of those studies were manually retrieved. After the studies were screened according to the inclusion and exclusion criteria, data were extracted and assessed, and Meta-analysis was performed using the Stata 12.0 software. Results A total of 11 studies with 23,939 patients were included. The Results of Meta-analyses showed that, RN and NSS had no significant difference in 5-year[RR=1.05, 95% CI(0.98, 1.13)], 7-year [RR=1.02, 95% CI (0.94, 1.10)], and 10-year [RR=1.30, 95% CI (0.96, 1.77)] overall survival (OS). Nevertheless, NSS had higher 5-year cancer specific survival (CSS) [RR=1.11, 95% CI (1.06, 1.16)], lower 5-year cancer specific mortality (CSM) [RR=0.70, 95% CI (0.55, 0.90)] and lower metastasis rate [RR=0.38, 95% CI(0.22, 0.66)]. Conclusion For the patients who are included in the study, NSS and RN is comparable in 5-year OS, 7-year OS, 10-year OS; NSS is superior to RN in 5-year CSS, 5-year CSM and metastasis rate.

Key words: T1b RCC, Prognosis, Radical nephrectomy, Nephron-sparing surgery, Meta-analysis

中图分类号: 

  • R737.11
[1] Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC):a literature review[J]. Cancer Treat Rev, 2008, 34(3):193-205.
[2] Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass[J]. Radiology, 2008, 249(1):16-31.
[3] Milonas D, Skulcius G, Baltrimavicius R, et al. Comparison of long-term results after nephron-sparing surgery and radical nephrectomy in treating 4-to 7-cm renal cell carcinoma[J]. Medicina (Kaunas), 2013, 49(5):223-228.
[4] 王权, 周文生. 小肾癌的治疗策略[J]. 中华全科医学, 2010, 8(12):1590-1592.
[5] Tomaszewski JJ, Smaldone MC, Uzzo RG, et al. Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery?[J]. BJU Int, 2015, 115(3):357-363.
[6] Antonelli A, Cozzoli A, Nicllai M, et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7cm[J]. Eur Urol, 2008, 53(4):803-809.
[7] Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [EB/OL]. [2012-06-15]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
[8] Badalato GM, Kates M, Wisnivesky JP, et al. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA:a propensity scoring approach[J]. BJU Int, 2012, 109(10):1457-1462.
[9] Crépel M, Jelares C, Perrotte P, et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma:a population-based assessment[J]. Urology, 2010, 75(2):271-275.
[10] Iizuka J, Kondo T, Hashimoto Y, et al. Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma[J]. Int J Urol, 2012, 19(11):980-986.
[11] Kim JM, Song PH, Kim HT, et al. Comparison of partial and radical nephrectomy for pT1b renal cell carcinoma[J]. Korean J Urol, 2010, 51(9):596-600.
[12] Leibovich BC, Blute M, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy[J]. J Urol, 2004, 171(3):1066-1070.
[13] Meskawi M, Becker A, Bianchi M, et al. Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma[J]. Int J Urol, 2014, 21(2):122-128.
[14] Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience[J]. J Urol, 2004, 171(6):2181-2185.
[15] Thompson RH, Siddiqui S, Lohse CM, et al. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors[J]. J Urol, 2009, 182(6):2601-2606.
[16] Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival[J]. Urology, 2010, 76(3):631-637.
[17] 胡波, 王涛, 刘继红,等. 保留肾单位手术和肾癌根治手术治疗局限性肾癌疗效比较的Meta分析[J]. 临床泌尿外科杂志, 2011, 26(5):324-327. HU Bo, WANG Tao, LIU Jihong, et al. Comparison of nephron-sparing surgery vs.radical phrectomy in patients with localized renal cell carcinoma:a Meta-analysis[J]. Journal of clinical Urology, 2011, 26(5):324-327.
[18] Kim SP, Murad MH, Thompson RH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors:a systematic review and Meta-analysis[J]. J Urol, 2012,188(1):51-57.
[19] Lucas SM, Stern JM, Adibi M, et al. Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques[J]. J Urol, 2008, 179(1):75-79.
[20] Lane BR, Russo P, Uzzo RG, et al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function[J]. J Urol, 2011, 185(2):421-427.
[21] Miller DC, Schonlau M, Litwin MS, et al. Renal and cardiovascular morbidity after partial or radical nephrectomy[J]. Cancer, 2008, 112(3):511-520.
[22] 郑殿宇, 王勤章, 丁国富, 等. 肾部分切除术和肾癌根治术治疗T1b期肾癌疗效比较的Meta分析[J]. 现代泌尿外科杂志, 2013, 18(4):342-346. ZHENG Dianyu, WANG Qinzhang, DING Guofu, et al. Comparison of partial vs radical nephrectomy in patients with T1b renal cell carcinoma:a Meta-analysis[J]. Journal of Modern Urology, 2013, 18(4):342-346
[1] 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3] 路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4] 李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5] 林萍珍,薛娇美,杨蓓,李萌,周麦琳,曹枫林. 基于Pearson相关系数的癌症患者创伤后成长与心理适应相关性的Meta分析[J]. 山东大学学报（医学版）, 2017, 55(9): 110-121.
[6] 宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[7] 杜金阁,陈慧,杨孝荣,吕明. STAT4 rs7574865位点单核苷酸多态性与系统性红斑狼疮易感性Meta分析[J]. 山东大学学报（医学版）, 2017, 55(5): 95-102.
[8] 孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[9] 董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[10] 林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[11] 周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[12] 张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[13] 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[14] 王丽丽,霍彬,王磊,汪浩,侯定坤,霍小东,王金焕,臧立,曹强,柴树德,王海涛. 亚肺叶切除联合125I粒子植入治疗早期肺癌有效性的Meta分析与系统评价[J]. 山东大学学报（医学版）, 2017, 55(10): 76-83.
[15] 李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发